Ricerca Biosciences Releases Foresight Similarity Analysis Service
Ricerca Biosciences
, a preclinical contract research organization providing services to the biopharmaceutical industry, has announced its similarity analysis service, Foresight™.
Foresight allows compound assay results to be compared against the assay results of a large reference set of pharmacologically active compounds. The tool helps predict
in vivo
effects from
in vitro
pharmacology data and provides insight into additional, non-obvious compound activities.
The analysis service allows scientists to discover clues to the possibilities of a compound. Foresight can be used to direct compound modification to avoid adverse effects and determine new indications for safe or novel compounds.
Ricerca has previous worked with clients to profile compounds in the discovery space. With the development of this tool, Ricerca can now offer interpretation and predictive analysis of pharmacological data.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
